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Abstract 
Nasopharyngeal carcinoma (NPC) is a kind of rare head and neck cancer in Japan. However, NPC has 
some unique features. It is one of the most popular cancers in southern China, Southeast Asia, the Arctic, 
and the middle East/north Africa. This distinctive racial, ethnical, and geographic predisposition to NPC 
implies that both genetic susceptibility and environmental factors contribute to the development of this 
tumor. NPC is an Epstein-Barr virus – associated tumor. Consistent elevation of EBV antibody titers is a 
well-established risk factor of development of NPC. Not only pathophysiological relationship, but also 
molecular mechanism of EBV-mediated carcinogenesis has been enthusiastically investigated. LMP1, an 
EBV primary oncogene, upregulates each step of metastasis, and contribute to highly metastatic feature of 
NPC. A tumor suppressor gene p53 is mostly intact and overexpressed in NPC whereas expression of p16, 
a cyclin-dependent kinase inhibitory protein, is downregulated in 2/3 of NPC. Intention modulated 
radiotherapy (IMRT) is now getting prevalent for the treatment of NPC because of complicated structure 
and location of nasopharynx. A good therapeutic result can be achieved by distributing a high dose to the 
tumor while keeping down normal tissue complications by reducing radiation dose to normal tissues. 
Chemotherapy is important to control distant metastasis of chemoradiosensitive NPC, and thus, should play 
an important role. However, most effective combination of anti-tumor drugs, protocol of chemoradiotherapy 
has not well-established. Finally, molecular targeting therapy, including targeting EBV gene product, has 
been developing and on the way to the clinical use. 
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1. Introduction 
 Nasopharyngeal carcinoma (NPC) is consistently associated with the Epstein-Barr 
virus (EBV), and is characterized by marked geographic and population differences in 
incidence[1,2].  As EBV infection is almost ubiquitous in the world, the development of cancer 
in a subset of infected population suggests that there are certain contributing factors in those 
who develop NPC. Indeed, studies of EBV and its associated tumors suggested specific 
interactions between environmental, genetic, and viral factors.  
 
2. Epidemiology 
 NPC develops extremely high incidence in southern China and Southeast Asia. The 
recent reported incidence of NPC among men and women in Hong Kong (geographically 
adjacent to Guangdong province) was 20 to 30 per 100,000 and 15 to 20 per 100,000 
respectively[1]. There is also increased incidence in northern Africa and the Inuits of Alaska[3], 
but it is an uncommon disease in most countries, and its age-adjusted incidence for both sexes is 
less than 1 per 100,000[2]. The incidence of NPC remains high among Chinese who have 
immigrated to other parts of Asia or North America, but is lower among Chinese born in North 
America than in those born in southern China[4,5]. Thus, it is suggested that genetic, ethnic and 
environmental factors could have some roles in the development of NPC.  
 
3. Pathology 
Regardless of geographic distribution or racial background, EBV is consistently 
detected in NPC[6]. Again, the consistent association with EBV and the remarkable patterns of 
incidence suggests the contribution of other co-factors to the development of this type of NPC. 
  The tumor presents with varying degrees of differentiation and has been classified by 
the World Health Organization into three categories[7]. Squamous cell carcinoma, WHO I 
tumors, are highly differentiated with characteristic epithelial growth patterns and keratin 
filaments. Non-keratinnizing, WHO II carcinomas, retain epithelial cell shape and growth 
patterns. Undifferentiated carcinomas, WHO III, do not produce keratin and lack a distributive 
growth pattern. Recently, based on the etiological view point, an alternative, simpler 
classification was proposed and this divided NPC into two histological types, namely squamous 
cell carcinomas (SCCs) and undifferentiated carcinomas of the nasopharyngeal type 
(UCNTs)[8]. This classification correlates with Epstein Barr virus serology tests. Those patients 
with SCCs have a lower EBV titer, while those with UCNTs have elevated titers. This 
classification is more applicable for epidemiological research and has also been shown to have a 
prognostic value. The UCNTs have a higher local tumor control rate with therapy, and a higher 
incidence of distant metastasis[9,10]. In North America, tumor histology in 25% of patients is 
Type I, 12% Type II, and 63% Type III while the corresponding histological distribution in 
southern Chinese patients is 2%, 3%, and 95% respectively[11,12].  
 
Premalignant lesions 
 In contrast to many cancers including head and neck cancers, premalignant lesions 
such as dysplasia or carcinoma in situ (CIS) are not usually detected in the development of NPC. 
The very low incidence of coexistent nasopharyngeal intraepithelial neoplasia with invasive 
cancer, approximately 3%, and the follow-up data all indicated a rapid progression of the 
initiated cell through the sequence of the dysplasia, CIS, and invasive cancer[13]. Thus, the 
biologic behavior of NPC is quite distinct from the malignant transformation and progression of 
head and neck carcinoma other than NPC, or cancer of the uterine cervix where premalignant 
dysplasia and CIS of the head and neck cancer and cervix cancer may persist for many years. 
EBV has been detected in all of the samples of preinvasive carcinoma (CIS) with EBERs 
expressions in the majority of cells. Moreover, expression of EBNA1, LMP1, LMP2A, and 
transcripts from BamHI A was detected in all of the premalignant lesions. A single restriction 
enzyme fragment study showed that preinvasive lesions contain clonal EBV and represent a 
focal cellular growth that developed from an EBV infected cell. The rarity of preinvasive lesions 
and the more frequent detection of CIS concomitant with invasive cancer suggest that the clonal 
infection by EBV is an early event in the development of NPC. 
 In other similar studies, example of milder dysplasia were identified that contained 
EBV in only a portion of cells[14]. This finding suggested that EBV infection occurred after 
some stimulus affected cell growth. Usually, EBV infection in epithelial cells is thought to result 
in viral replication. The fate of cells in which herpesvirus replicate is not malignant 
transformation but cell lysis. Thus, it is also possible that some preceding genetic change affects 
viral infection such that a latent EBV infection is established with expression of potent genes 
such as LMP1 and LMP2 that significantly affect cell growth. A loss of the p16 tumor 
suppressor gene was identified in early, EBV-negative lesions[15]. The expression of EBV 
transforming proteins, in combination with p16 loss, could result in rapid progression to 
invasive malignancy. 
 
4. Gene expression 
i) EBV gene expression and clinical feature in NPC 
 Three EBV-encoded genes, the EBV-encoded small nuclear RNAs (EBERs), latent 
membrane protein (LMP)1 and 2A are detected in NPC samples. Many studies have identified 
abundant transcription of in EBV genome positive NPC cells[16,17]. LMP1 upregulates all 
steps of metastasis, such as down regulation of cell-cell adhesion, degradation of basement 
membrane and interstitial stroma, upregulation of tumor cell motility, and angiogenesis. 
Upregulation of metastasis related steps in the early stage reflect highly metastatic feature of 
NPC[18-24]. In fact, most common clinical symptom is neck mass[25]. The role on LMP2A in 
NPC is still obscure.  
 
ii) Tumor suppressor genes 
 As with all cancers, the development of NPC involves the loss of tumor suppressors. 
However, the mechanisms of losing tumor suppressors in NPC seem somewhat unique. 
 
a) High Levels of p53 Are Found in NPC  
 p53 is a hallmark tumor suppressor that induces cell cycle arrest in response to DNA 
damage. In most head and neck cancers, low levels of p53 are due to mutations[26]. However, 
p53 in NPC does not follow this classic pattern. NPC cells have increased levels of p53[27]. 
with high LMP1 levels correlating with higher p53 expression[28,29]. p53 mutations are 
relatively rare in NPC, so the vast majority of expressed p53 is wild type[30]. The wild-type 
p53 fails to induce apoptosis in NPC because it is inactivated through 2 mechanisms—loss of 
p14 and excess DN-p63. p14 maintains p53 stability by inhibiting its proteolysis[31].; in NPC, 
p14 levels are low via promoter hypermethylation,99 thus allowing for more efficient p53 
degradation. p63 is actually a homologue of p53 with similar DNA binding sequences to 
p53[32].  There is a mutated version of p63 in NPC, called DN-p63, which lacks the 
N-terminal transactivation domain needed to activate apoptosis[33]. The DN-p63 isoform binds 
the normal p63 (and p53) DNA sequences, thus preventing normal p63 or p53 from binding, but 
fails to induce apoptosis because of loss of the N-terminal sequence. The reason for high p53 
levels in NPC is unclear. High levels of normal p53 may be advantageous to NPC development 
because tumor cells with normal p53 are immune to JNK-induced apoptosis[34]. Alternatively 
the increased wildtype p53 may simply be the natural response to EBV infection[35]. In light of 
this, it appears that the loss of p53 is not critical for NPC development, suggesting that 
inactivation of other tumor suppressors is likely required for NPC tumorigenesis.  
 
b) p16 Activity Is Decreased  
 p16 is a cyclin-dependent kinase inhibitory protein (CKI) that suppresses activity and 
is frequently inactivated in cancer[36]. The normal function of p16 is to suppress cdk4, an 
enzyme that controls the G1/S checkpoint by negatively regulating cyclin D1 activity. Therefore, 
loss of p16 results in cyclin D1 overactivation and subsequent increases in G1/S phase 
transitions[37]. In head and neck cancers, including NPC, the majority of head and neck cancers 
exhibit low p16 levels with high pRb levels[38,39]. In HNSCC, the most common mechanism 
of p16 inactivation is homozygous deletion of the gene followed by hypermethylation of the 
gene[40]. Similarly, NPC cell lines have low levels of p16 secondary to hypermethylation of the 
p16, but this epigenetic alteration may be mediated by LMP1-induced c-Jun/JunB heterodimer 
formation, which activate DNA methyltransferase[41]. Additionally, LMP1 inactivates p16 by 
inducing cytoplasmic accumulation of E2F4/5 and Ets2, which are nuclear proteins required for 
normal p16 activity. Ets2 is a key transcription factor for p16 expression and LMP1 directly 
causes its translocation from the nucleus to the cytoplasm[42]. E2F4/5 are proteins required for 
the activation of p16-induced cell cycle arrest in G1, and their nuclear localization is dependent 
on binding to nuclear pRb[43]. LMP1 induces the translocation of E2F4/5 from the nucleus into 
the cytoplasm by causing E2F4/5 to dissociate from pRb proteins. LMP1 further promotes 
cytoplasmic accumulation of Ets2 and E2F4/5 by mediating their binding to a nuclear export 
protein called chromosome maintenance region 1 (CRM-1). About two thirds of NPCs exhibit 
low p16 levels, indicating that p16 downregulation is not critical to NPC development. However, 
the absence of p16 is still important to NPC.  Patients with NPC tumors with low p16 levels 
have a worse prognosis because this is associated with decreased radiosensitivity and higher 
rates of tumor recurrence[44,45]. The reason for this may be that the greatest radiosensitivity in 
cells is just prior to DNA synthesis and loss of p16 increases the number of cells in S phase.146 
There is some data that pretreatment of NPC patients with p16 gene therapy before radiation can 
improve outcomes; the presumed mechanism behind this is that by normalizing p16 levels, the 
cell cycle is slowed at the G1/S checkpoint and the number of cells in G1 increased[46]. 
However, further clinical trials are needed to evaluate the effectiveness of this treatment. 
 
5. STAGING AND TREATMENT 
i) Prognostic factors 
 The tumor, nodes, and metastases (TNM) staging for NPCs is the most important 
prognostic factor[47]. Indeed, most other known prognostic factors are directly or indirectly 
related to the extent or bulk of the tumor. 
A study reported in 1992 showed that the tumor's histological type and the radiotherapy dosage 
and coverage were also significant independent prognostic factors[48]. The histological type, 
WHO Type I patients frequently seen among the Caucasian population were found to be 
associated with adverse prognosis[49]. 
 A large variation of tumor volume is present in T stages and primary tumor volume 
represents an independent prognostic factor of local control. Its validity has been confirmed in 
patients with T3 and T4 tumors, and there is an estimated 1% increase in risk of local failure for 
every 1 cm3 increase in primary tumor volume[50].  
Amount of circulating EBV DNA in NPC, estimated to reflect the tumor load, has a positive 
correlation with disease stage. It has been shown to have prognostic importance[51]. 
 
ii) Radiotherapy 
 NPC, most of which has wild-type p53, is highly radiosensitive. Thus, radiotherapy 
(RT) plays a central role in the treatment of all stages of NPC without distant metastases. The 
patients with distant metastasis may be treated with RT in case of controlling local disease has 
benefit for improve the patients’ QOL.  
Conventional 2dimensional (2D) RT successfully controlled T1 and T2 tumors in between 75% 
to 90% of cases, and T3 and T4 tumors in 50% to 75% of cases[52,53]. Nodal control is 
achieved in 90% for N0 and N1 cases, but the control rate drops to 70% for N2 and N3 
cases[52]. As interrupted or prolonged treatment reduces the benefits of RT, every effort should 
be made to maintain the treatment schedule[54]. Because of the high incidence of occult neck 
node involvement, prophylactic neck radiation is usually recommended[55]. Good loco-regional 
control should be the prime objective of treatment, as loco-regional relapses represent a 
significant risk factor for the development of distant metastases[56]. 
 For T1 and T2 tumors, a booster dose using intracavitary brachytherapy improved 
tumor control by 16%[53]. However, it is probably better to reserve stereotactic radiosurgery for 
the treatment of persistent and recurrent NPCs, because of the undesirable side effects 
associated with hypofractionated treatment[57-59]. RT for NPC is challenging because the 
nasopharynx is anatomically surrounded by an array of radiosensitive structures such as the 
brain stem, spinal cord, pituitary-hypothalamic axis, temporal lobes, eyes, middle and inner ears, 
and parotid glands. As NPCs tend to infiltrate and spread towards these normal organs, the 
irradiation target volumes in NPC are very irregular. For patients with early disease, since they 
have a good chance of survival, radiation toxicities in these even non-critical structures would 
affect the quality of life of survivors. However, for patients with locally advanced disease like 
those with skull base or intracranial extension, the challenge lies in achieving adequate tumor 
controlling dose to the primary tumor with sparing the critical organs. 
 The major limitations of conventional 2D radiotherapy for NPC can now be overcome 
with 3 dimensional (3D) conformal RT and intension modulated radiotherapy (IMRT)[60,61]. 
IMRT is an advanced form of 3D conformal radiotherapy, conforming high dose to tumor while 
conforming low dose to normal tissues. The ability of IMRT to deliver a more conformal 
radiation dose to the target area and spare surrounding structures seems to decrease the toxicity 
of chemoradiotherapy[62]. A good therapeutic result can be achieved by distributing a high dose 
to the tumor while keeping down normal tissue complications by reducing radiation dose to 
normal tissues. Some researchers reported excellent local control of more than 90% in NPC 
achieved with IMRT[63], even among patients with advanced T3-4 diseases[64]. Reports also 
shown preservation of salivary function and improve quality of life of survivors after 
IMRT[65,66]. A recent multicentre study also showed that the excellent 90% local control rate 
with IMRT as reported from single institutions are reproducible in multi-institutional setting[67]. 
Thus, IMRT has gradually been considered as the new standard RT for NPC. 
 
iii) Chemotherapy 
 As the development of RT achieves good local control, distant metastatic failure 
become the pattern of recurrence, especially among those with loco-regionally advanced disease, 
which could hardly be controlled with conventional 2D RT. As radiosensitivity well correlates 
with chemosensitivity, NPC is also chemosensitive. Many clinical studies investigated 
advantage of chemotherapy for NPC. However, most of the early studies were non-randomized 
and the results are not conclusive[68-70]. So far, there were only 5 reported randomized trials 
on combined chemotherapy and RT for NPC[69,71-74]. In the early randomized trials, 
induction chemotherapy is the most often studied combination[69,72,74]. The rationale for 
induction chemotherapy is to reduce tumor load of loco-regional disease before start of RT and 
also early use of systemic treatment for eradication of micro-metastases. The International 
Nasopharyngeal Carcinoma Study Group[69], using combination of bleomycin, epirubicin and 
cisplatin, showed a significant improvement of disease-free survival, but, did not show 
improvement of overall survival. This discrepancy may be due to the increased 
treatment-related death among patients on induction chemotherapy compared to RT alone (8% 
vs 1%). 
 A pivotal study was reported by the Head and Neck Intergroup in 1998, using 
concurrent RT with cisplatin (100 mg/ m2 day1, 22, 43) followed by adjuvant cisplatin and 
5-fluouracil (5-FU) (cisplatin 80 mg/m2 day1 and 5-FU 1,000 mg/ m2 /day, day1-4, 4 weeks 
cycles for 3 cycles)[73]. Compared with RT alone, chemoradiation (CRT) significantly 
improved progression free survival and overall survival. The pattern of disease failure showed 
reduction of both loco-regional and distant failure with CRT. 
 After report of the Intergroup 0099 Study, randomized trials using similar design were 
performed in endemic regions in Asia, to validate the Intergroup results. Three randomized 
trials were subsequently reported from Hong Kong[75], Singapore[76], and China [77] 
respectively. The HK study, using the same chemotherapy regime as the Intergroup study 0099, 
showed improved local control with CRT. However, There was no significant difference 
between distant control and overall survival[75]. On the other hand, the Singapore and China 
studies both used a variation of dosing of cisplatin from the 0099 regimes, using lower dose of 
cisplatin more frequently, showed significant reduction of distant metastases and improvement 
of both disease-free and overall survival with CRT[76,77]. 
 Although some reports resulted in unfavorable feasibility, it is now generally accepted 
that Intergroup 0099 is feasible to the NPC in Asian, including endemic and non-endemic areas. 
The 0099 study showed that concurrent CRT was the most efficacious. There were 3 
randomized trials that evaluated adjuvant chemotherapy all of which showed negative 
results[71,78,79]. Thus, there is still debate on the efficacy of the adjuvant chemotherapy in the 
Intergroup 0099. Compared to the Intergroup 0099 Trial, alternating CRT in Aichi Cancer 
Institute was characterized by a decreased total dose of CDDP (540 mg/m2 in the Intergroup 
0099 vs. 300 mg/m2 in Aichi), a shorter treatment period (130 days in the Intergroup 0099 vs. 
83 days in Aichi), a higher treatment completion rate (55%: 43 of 78 cases in the Intergroup 
0099 vs. 80%: 70 of 87 cases in Aichi), and a higher 3-year overall survival rate (78% in the 
Intergroup 0099 vs. 92% in Aichi )[80]. Although the final therapeutic value of this alternating 
CRT cannot be currently evaluated, this method can be used in a controlled clinical trial in the 
future to compare therapeutic results with those of the concurrent CRT. 
 Impairment of quality of life, mainly attributable to radiation is a serious problem for 
survivors of NPC treated with radiotherapy or CRT[81,82]. The use of chemotherapy in more 
advanced cases adds to the side effects, which include ototoxicity associated with cisplatin.  
 
iv) Managenent of residual or recurrent disease 
 Despite concomitant CRT generated remarkable improvement in the management of 
nasopharyngeal carcinoma, some patients still developed loco- regional recurrence presenting as 
persistent or recurrent tumor. Early detection is essential for any form of salvage therapy to be 
successful. Generally, planned neck dissection is not recommended. If a complete remission has 
been obtained in the neck, no salvage surgery is considered necessary and if a metastatic mass 
in the neck does not disappear completely, a neck dissection is performed.  
 FDG-PET, definitely powerful for detection of primary nasopharyngeal carcinoma and 
in particular, has a high-negative-predictive value and is considered reliable to evaluate the 
response to treatment, is not always superior to other imaging studies such as computed 
tomography or MRI in detecting residual or recurrent disease. Residual or recurrent tumor in the 
cervical lymph nodes after radiotherapy is notoriously difficult to confirm, as in some lymph 
nodes only clusters of tumor cells are present [83]. Thus, sometimes the diagnosis was only 
confirmed after salvage surgery. The other argument is the type of dissection. Wei et al 
analyzed serial sections in a series of whole-neck dissection specimens and found that all levels 
of the neck compartment had the potential of being involved with level II being the most 
common (53%). They also found the incidence of extranodal extension to be 84% in the patients 
with extensive recurrent or persistent disease in the neck, and concluded that RND with 
additional brachytherapy is a treatment of choice for such selected patients [83]. On the contrary, 
Khafif advocated that the neck dissection should be tailored to the patient and although the 
procedure of choice is currently an RND due to lack of data, one may consider less aggressive 
procedures in selected patients with limited persistent disease [84]. Therefore, as is the case with 
the management of recurrent and residual neck disease in the other head and neck cancers, 
trends in the salvage neck dissection for residual neck mass has still been controversial. 
 Aggressive salvage treatment for locally recurrent NPC is warranted, especially when 
the disease is confined to the nasopharynx [85]. Even for patients with synchronous 
loco-regional failures, aggressive treatment should be considered for selected patients. There are 
three popular approaches for nasopharynx, transoral (transpalatal), transmaxillar (maxillar 
swing), and endoscopic approaches. Close evaluation for the indication of surgical treatment 
and approach to the nasopharynx. Patients whose local disease was treated by surgical resection 
had a 3-year local control rate of 71% compared with 38% by reirradiation using brachytherapy 
or external radiotherapy. For regional disease, the 3-year nodal control rate after radical neck 
dissection was 65% compared with 24% by reirradiation[86]. 
 Immunotherapy and anti-viral drug, targeting EBV gene products, are not applicable 
for all recurrent cases, either. It is desired to establish the way to identify the patients who are 
expected to have benefits from these treatments [87-89].    
 
6. Conclusion 
 There have been remarkable progress in the understanding of molecular mechanism of 
EBV-mediated carcinogenesis and treatment modality in nasopharyngeal carcinoma. However, 
many issues such as “ How EBV infect to nasopharyngeal mucosa?” “Why racial/ethnic 
predisposition exist?” How EBV-mediated carcinogenesis triggered in healthy carriers?”, have 
been unsolved. The cue to answer these subjects would be found by physician scientists 
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